var data={"title":"Pyogenic granuloma (Lobular capillary hemangioma)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pyogenic granuloma (Lobular capillary hemangioma)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/contributors\" class=\"contributor contributor_credentials\">Leslie P Lawley, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 11, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3446791\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyogenic granuloma (PG) or lobular capillary hemangioma [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/1\" class=\"abstract_t\">1</a>] is a benign vascular tumor of the skin or mucous membranes characterized by rapid growth and friable surface. PG occurs at any age, although it is seen more often in children and young adults. Surgical treatment is usually required because PG rarely resolves spontaneously and often bleeds repeatedly and profusely.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of pyogenic granuloma. Other benign and malignant vascular tumors are discussed separately. (See <a href=\"topic.htm?path=infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications&quot;</a> and <a href=\"topic.htm?path=rapidly-involuting-congenital-hemangioma-rich-and-noninvoluting-congenital-hemangioma-nich\" class=\"medical medical_review\">&quot;Rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH)&quot;</a> and <a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment&quot;</a> and <a href=\"topic.htm?path=aids-related-kaposi-sarcoma-staging-and-treatment\" class=\"medical medical_review\">&quot;AIDS-related Kaposi sarcoma: Staging and treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1291997\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyogenic granuloma (PG) occurs in patients of all ages with a peak incidence in the second and third decades of life [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/2,3\" class=\"abstract_t\">2,3</a>]. In children, the average age at diagnosis is 6 to 10 years and there is a predilection for males [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Mucosal PG is more common in adult women than in men or children [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/6,7\" class=\"abstract_t\">6,7</a>]. About 2 percent of pregnant women develop an intraoral PG in the first five months of pregnancy [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-skin-hair-nails-and-mucous-membranes#H7\" class=\"medical medical_review\">&quot;Maternal adaptations to pregnancy: Skin, hair, nails, and mucous membranes&quot;, section on 'Vascular tumors'</a>.)</p><p class=\"headingAnchor\" id=\"H3446805\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the name suggests an infectious etiology, the cause of pyogenic granuloma (PG) is unknown. Most theories on pathogenesis revolve around PG as a hyperplastic, neovascular response to an angiogenic stimulus with imbalance of promoters and inhibitors [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/3,9\" class=\"abstract_t\">3,9</a>]. Angiogenic growth factors such as vascular endothelial growth factor (VEGF) and decorin, transcription factors (pATF2 and pSTAT3), and mitogen-activated protein kinase (MAPK) signal transduction pathway proteins are overexpressed in PGs, but their exact role is undetermined [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/9-11\" class=\"abstract_t\">9-11</a>]. A whole-exome sequencing study of 40 PG lesions found <em>HRAS </em>somatic mutations in four tumors, supporting a role for the RAS-MAPK pathway in the development of PG [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/12\" class=\"abstract_t\">12</a>]. An analysis of 11 PGs revealed embryonic stem cell markers in the endothelial cells and a more differentiated pattern in the interstitial cells suggesting de novo vasculogenesis from the primitive stem cells [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/13\" class=\"abstract_t\">13</a>].</p><p>Trauma has been suggested as a trigger, although only 7 to 23 percent of patients with PG report a previous injury at the site [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/4,5\" class=\"abstract_t\">4,5</a>]. In a series of patients with periungual or subungual PG, local injury (eg, acute mechanical trauma, onycholysis, or chronic nail manipulation) was reported in 58 percent of cases [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/14\" class=\"abstract_t\">14</a>]. Patients who have undergone hematopoietic cell transplant have been reported to develop mucosal PG thought to be related to the trauma of oral graft-versus-host disease or medications taken post-transplant [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/15\" class=\"abstract_t\">15</a>].</p><p>PG may also be drug-induced [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/9,14,16-25\" class=\"abstract_t\">9,14,16-25</a>]. In one study, about 30 percent of cases of periungual or subungual PG were related to a systemic medication [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/14\" class=\"abstract_t\">14</a>]. Offending medications include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic and topical retinoids</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidermal growth factor receptor and tyrosine kinase inhibitors (eg, <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/26\" class=\"abstract_t\">26</a>])</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">Capecitabine</a> and <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>5-fluorouracil </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">Cyclosporine</a>, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">Docetaxel</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulocyte colony-stimulating factor</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human immunodeficiency virus (HIV) protease inhibitors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>BRAF inhibitors (eg <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a>, encorafenib [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/27\" class=\"abstract_t\">27</a>]) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents#H10\" class=\"medical medical_review\">&quot;Cutaneous side effects of conventional chemotherapy agents&quot;, section on 'Nail disorders'</a> and <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy#H2\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;, section on 'EGFR inhibitors'</a>.)</p><p/><p>PG may occur within a capillary vascular malformation (ie, port wine stain [PWS] (<a href=\"image.htm?imageKey=DERM%2F59124%7EPEDS%2F58831\" class=\"graphic graphic_picture graphicRef59124 graphicRef58831 \">picture 1A-B</a>)) spontaneously or following laser treatment [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/28-31\" class=\"abstract_t\">28-31</a>]. This supports a hypothesis that PG arises from microscopic arteriovenous anastomoses, which may be found in capillary malformations and in common locations for PG such as acral sites and oronasal mucosa [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/28\" class=\"abstract_t\">28</a>]. In one study of 10 PGs arisen in a PWS, eight were found to harbor a <em>BRAF</em> c.1799T&gt;A mutation and one a NRAS mutation; in addition, a <em>GNAQ</em> c.548G&gt;A mutation was identified in all but one PG and in the respective underlying PWS [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/32\" class=\"abstract_t\">32</a>]. These findings indicate that PGs originate from endothelial cells of the PWS and that BRAF mutations may act as a second hit on the <em>GNAQ</em> mutation activated MAPK-signaling pathway in endothelial cells, leading to tumor growth. The report of PG arising in the setting of selective BRAF inhibitor treatment supports this theory [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes#H962310\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;, section on 'Pathogenesis'</a>.)</p><p class=\"headingAnchor\" id=\"H3446812\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyogenic granuloma (PG) starts as a small red papule that grows rapidly over weeks to months and then stabilizes (<a href=\"image.htm?imageKey=DERM%2F60189\" class=\"graphic graphic_picture graphicRef60189 \">picture 2A</a>). The size rarely exceeds one centimeter. Spontaneous regression is rare and, if left untreated, the lesion may persist indefinitely. The lesion may be pedunculated or sessile and its base is often surrounded by a characteristic collarette of acanthotic epidermis (<a href=\"image.htm?imageKey=DERM%2F52128%7EDERM%2F67395%7EDERM%2F52429\" class=\"graphic graphic_picture graphicRef52128 graphicRef67395 graphicRef52429 \">picture 3A-C</a>). PG bleeds profusely after minor trauma and may become ulcerated. Bleeding is difficult to control and often recurrent.</p><p>The skin is more commonly involved than the mucosa. In a review of 325 cases of PG, 86 percent were located on the skin [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/2\" class=\"abstract_t\">2</a>]. In adults, PG occurs most often on the trunk or extremities, whereas in children lesions are more commonly seen on the head and neck [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/2-5\" class=\"abstract_t\">2-5</a>]. Mucosal PGs usually occur in the oral cavity. The predominant sites are the lip and gingival mucosa (<a href=\"image.htm?imageKey=DERM%2F60189%7EPC%2F66965\" class=\"graphic graphic_picture graphicRef60189 graphicRef66965 \">picture 2A-B</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/1,6\" class=\"abstract_t\">1,6</a>]. Rarely, PG develops in the gastrointestinal tract; patients may be asymptomatic or present with overt bleeding, anemia, or dysphagia [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/33\" class=\"abstract_t\">33</a>]. </p><p>Most PGs arise on normal appearing skin or mucosal surfaces. However, PG may arise in a capillary vascular malformation (ie, port wine stain) or arteriovenous malformation, sometimes following laser treatment or cryotherapy [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/28,29,34-37\" class=\"abstract_t\">28,29,34-37</a>]. </p><p>Most lesions are solitary but there are reports of multiple PGs arising in a disseminated fashion. Disseminated PGs may occur in otherwise healthy individuals or in association with drug eruptions, burn injury, or treatment with anti-CD20 monoclonal antibodies or granulocyte colony-stimulating factor [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/24,38-41\" class=\"abstract_t\">24,38-41</a>]. Multiple grouped PGs may develop in infants and young children over a preexisting vascular malformation, particularly capillary or arteriovenous malformations [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Uncommonly, multiple PGs develop as satellite lesions spontaneously or following treatment of a solitary PG (<a href=\"image.htm?imageKey=DERM%2F62759\" class=\"graphic graphic_picture graphicRef62759 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/43-45\" class=\"abstract_t\">43-45</a>]. This phenomenon usually occurs in children and resolves spontaneously in 6 to 12 months [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/45\" class=\"abstract_t\">45</a>].</p><p>Congenital PGs, solitary or disseminated, are extremely rare and difficult to discern from infantile hemangiomas without histopathologic examination and glucose transporter 1 (GLUT-1) staining [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/46,47\" class=\"abstract_t\">46,47</a>]. (See <a href=\"#H3446819\" class=\"local\">'Pathology'</a> below.)</p><p class=\"headingAnchor\" id=\"H3446819\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Low power examination of pyogenic granuloma (PG) shows a polypoid lesion with a lobular arrangement of capillaries at the base (<a href=\"image.htm?imageKey=DERM%2F71936\" class=\"graphic graphic_picture graphicRef71936 \">picture 5A</a>). The epidermis overlying the pedunculated mass may be flattened, atrophic, and often ulcerated. At the base of the lesion, the epidermis is acanthotic with inward growth representing the &quot;epithelial collarette&quot; [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/5\" class=\"abstract_t\">5</a>]. The pedunculated morphology and epithelial collarette are seen in most PG occurring on the skin but only in 30 percent of mucosal PG, mainly in those involving the oral mucosa [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>The vessel lumina vary in size. Superficial stromal edema, capillary dilatation, inflammation, and granulation tissue may be seen [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>On higher power, plump endothelial cells line the capillaries (<a href=\"image.htm?imageKey=DERM%2F50978\" class=\"graphic graphic_picture graphicRef50978 \">picture 5B</a>). They are surrounded by a mixed cells population of fibroblasts, mast cells, lymphocytes, plasma cells and polymorphonuclear leukocytes [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>Immunohistochemistry staining is negative for glucose transporter 1 (GLUT-1), but positive for Wilms tumor I gene expression, factor VIII antigen, CD31, CD34, and Ulex europeus agglutinin lectin [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/48-51\" class=\"abstract_t\">48-51</a>]. GLUT-1 stain is helpful in differentiating PG from infantile hemangiomas, which usually stain positively.</p><p class=\"headingAnchor\" id=\"H3446826\"><span class=\"h1\">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of pyogenic granuloma (PG) is usually straightforward, based upon the clinical history of an erythematous, dome-shaped papule that bleeds easily and has developed over a few days to weeks (<a href=\"image.htm?imageKey=DERM%2F52128%7EDERM%2F52429\" class=\"graphic graphic_picture graphicRef52128 graphicRef52429 \">picture 3A, 3C</a>).</p><p>Dermoscopic examination reveals a pink homogenous papule with a white collarette of scale; white intersecting lines representing the fibrous septa seen on histopathology may also be seen (<a href=\"image.htm?imageKey=DERM%2F57957\" class=\"graphic graphic_picture graphicRef57957 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/52\" class=\"abstract_t\">52</a>]. </p><p>Histopathologic confirmation is helpful in excluding disorders that may mimic PG. Excisional biopsy provides the optimal pathologic specimen for excluding malignant tumors. However, any specimens obtained by other treatment modalities such as shave excision or curettage should be sent for histopathologic examination. (See <a href=\"#H3446819\" class=\"local\">'Pathology'</a> above and <a href=\"#H3446840\" class=\"local\">'Management'</a> below.) </p><p>The disorders that should be differentiated from PG include [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/4,53\" class=\"abstract_t\">4,53</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infantile hemangioma</strong> &ndash; Infantile hemangiomas present as bright red papules, nodules, or plaques that appear in early infancy and grow rapidly (<a href=\"image.htm?imageKey=PEDS%2F60004\" class=\"graphic graphic_picture graphicRef60004 \">picture 7</a>). Unlike PG, bleeding is uncommon and is usually well controlled with firm pressure. Infantile hemangiomas involute, whereas PG do not regress spontaneously [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/46\" class=\"abstract_t\">46</a>]. Histologic examination during the proliferation stage demonstrates superficial proliferating angioblastic endothelial cells with few capillary lumina. In contrast to PG, immunohistochemistry staining is positive for glucose transporter 1 (GLUT-1); however, in most cases the diagnosis of infantile hemangioma is made without biopsy. (See <a href=\"topic.htm?path=infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications\" class=\"medical medical_review\">&quot;Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Spindle and epithelial cell nevi (Spitz nevi)</strong> &ndash; Spitz nevi present as brown or red dome shaped firm papules with an intact surface. Typically, there is not a history of bleeding. On dermoscopic examination, blue, brown or black pigment may be visible. Histologically, Spitz nevus is a symmetrical and well-defined compound nevus consisting of spindle-shaped or epithelioid melanocytes. (See <a href=\"topic.htm?path=spitzoid-melanocytic-neoplasms-spitz-nevus-and-atypical-spitz-tumors\" class=\"medical medical_review\">&quot;Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Glomus tumor</strong> &ndash; Glomus tumor is a rare, benign neoplasm composed of cells resembling smooth cells of the normal glomus body [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/54\" class=\"abstract_t\">54</a>]. Glomus tumor is usually located in skin areas rich in glomus bodies (eg, the subungual regions of digits or the deep dermis of the palm, wrist, forearm, and foot) and presents as a red-purple vascular papule or nodule associated with paroxysmal pain, cold sensitivity, and tenderness. Glomus tumor does not bleed or ulcerate (<a href=\"image.htm?imageKey=DERM%2F77094\" class=\"graphic graphic_picture graphicRef77094 \">picture 8</a>). Histologic examination demonstrates a solid mass of glomus cells, vessels, and smooth muscle cells.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Common wart</strong> &ndash; Common warts present as solitary or multiple, firm, hyperkeratotic papules that occasionally may be necrotic at the surface or bleed (<a href=\"image.htm?imageKey=DERM%2F70615%7EDERM%2F56924\" class=\"graphic graphic_picture graphicRef70615 graphicRef56924 \">picture 9A-B</a>). Clinical or dermoscopic examination after removing the hyperkeratotic layer reveals thrombosed vessels (&quot;black dots&quot;). (See <a href=\"topic.htm?path=cutaneous-warts-common-plantar-and-flat-warts\" class=\"medical medical_review\">&quot;Cutaneous warts (common, plantar, and flat warts)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Amelanotic melanoma</strong> &ndash; Amelanotic melanoma is often misdiagnosed as a pyogenic granuloma. On dermoscopic examination, amelanotic melanoma may have subtle melanocytic structures or irregular vascular patterns (<a href=\"image.htm?imageKey=DERM%2F62791\" class=\"graphic graphic_picture graphicRef62791 \">picture 10</a>). Histologic examination is necessary for a correct diagnosis. (See <a href=\"topic.htm?path=melanoma-clinical-features-and-diagnosis#H55929575\" class=\"medical medical_review\">&quot;Melanoma: Clinical features and diagnosis&quot;, section on 'Amelanotic melanoma'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Squamous cell carcinoma</strong> &ndash; Squamous cell carcinoma (SCC) usually presents as a slow growing lesion with a hyperkeratotic surface (<a href=\"image.htm?imageKey=DERM%2F60026\" class=\"graphic graphic_picture graphicRef60026 \">picture 11</a>); keratoacanthoma-type SCC develops quickly with a central keratotic core, but is not friable (<a href=\"image.htm?imageKey=DERM%2F55042\" class=\"graphic graphic_picture graphicRef55042 \">picture 12</a>). Histologic examination clarifies the diagnosis. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-cutaneous-squamous-cell-carcinoma-scc\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Basal cell carcinoma</strong> &ndash; Nodular basal cell carcinoma presents as a pearly slow-growing papule, sometimes with surface crust or ulceration (<a href=\"image.htm?imageKey=ONC%2F61190%7EDERM%2F65704\" class=\"graphic graphic_picture graphicRef61190 graphicRef65704 \">picture 13A-B</a>). On dermoscopy, blue globules, large blue-gray ovoid nests, arborizing telangiectasias, leaf-like areas, or spoke-wheel structures may be seen (<a href=\"image.htm?imageKey=DERM%2F61313\" class=\"graphic graphic_picture graphicRef61313 \">picture 14</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/52\" class=\"abstract_t\">52</a>]. Histology is necessary to confirm the diagnosis. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-features-of-basal-cell-carcinoma#H21\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical features of basal cell carcinoma&quot;, section on 'Clinical presentation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Kaposi sarcoma</strong> &ndash; Kaposi sarcoma presents as slow-growing violaceous papules and plaques, usually multiple in number. Elevated or polypoid lesions are rare and may mimic pyogenic granuloma, although profuse bleeding unusual (<a href=\"image.htm?imageKey=PC%2F80323\" class=\"graphic graphic_picture graphicRef80323 \">picture 15</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/55\" class=\"abstract_t\">55</a>]. Biopsy is required for definitive diagnosis. (See <a href=\"topic.htm?path=aids-related-kaposi-sarcoma-staging-and-treatment\" class=\"medical medical_review\">&quot;AIDS-related Kaposi sarcoma: Staging and treatment&quot;</a> and <a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bacillary angiomatosis</strong> &ndash; Bacillary angiomatosis is caused by infection with <em>Bartonella henselae</em> or <em>Bartonella quintana</em> and usually occurs in HIV-infected or immunocompromised patients. Multiple vascular papules and nodules similar to PG occur (<a href=\"image.htm?imageKey=ID%2F78497%7EID%2F76323\" class=\"graphic graphic_picture graphicRef78497 graphicRef76323 \">picture 16A-B</a>). Histologic examination shows lobular vascular proliferations of vessels lined by plump endothelial cells with clusters of neutrophils and lymphocytes (<a href=\"image.htm?imageKey=ID%2F54383\" class=\"graphic graphic_picture graphicRef54383 \">picture 17</a>). Warthin-Starry stain demonstrates clumps of small pleomorphic bacilli (<a href=\"image.htm?imageKey=ID%2F62100\" class=\"graphic graphic_picture graphicRef62100 \">picture 18</a>). (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients#H2\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients&quot;, section on 'Bacillary angiomatosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Angiolymphoid hyperplasia with eosinophilia </strong>&ndash; Angiolymphoid hyperplasia with eosinophilia is a rare disorder presenting as solitary or multiple erythematous or violaceous papules or nodules in the head and neck region. Histologically, a prominent vascular proliferation with large epithelioid endothelial cells is associated with an infiltrate of lymphocytes and eosinophils. </p><p/><p class=\"headingAnchor\" id=\"H851335\"><span class=\"h1\">NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is little information about the natural history of untreated pyogenic granuloma (PG). Most lesions are treated because of frequent bleeding, ulceration, or cosmetic appearance. In clinical experience, pyogenic granulomas generally do not spontaneously involute, but there are exceptions:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Spontaneous regression of PG over the course of 6 to 18 months has been reported in a few patients [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug-induced PG may regress upon discontinuation of the offending medication [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/14\" class=\"abstract_t\">14</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral pyogenic granulomas occurring in pregnant women usually regress after childbirth [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/56\" class=\"abstract_t\">56</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Satellite PGs that develop spontaneously or after treatment of a solitary PG (<a href=\"image.htm?imageKey=DERM%2F62759\" class=\"graphic graphic_picture graphicRef62759 \">picture 4</a>) also may resolve after 6 to 12 months [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/45\" class=\"abstract_t\">45</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In disseminated PG, the majority of lesions eventually resolve spontaneously [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/47,57\" class=\"abstract_t\">47,57</a>].</p><p/><p class=\"headingAnchor\" id=\"H3446840\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H851348\"><span class=\"h2\">Therapeutic approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment is usually required for pyogenic granuloma (PG) because of frequent ulceration and bleeding. There are few randomized trials comparing treatments for PG and no consensus regarding the optimal approach. Because malignant tumors can mimic PG, it is desirable that the technique(s) selected for removal of PG yield material for histopathologic analysis. Additional factors influencing the choice of treatment are the morphology, size, and location of the lesion, patient's age, and risk of recurrence and scarring. Provoking factors (eg, trauma, foreign body, or medication), if present, should be prevented, removed, or discontinued if feasible.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For pedunculated PG, we suggest shave excision or curettage followed by cautery of the base rather than full-thickness surgical excision. Scars are less conspicuous with shave excision or curettage than with full-thickness excision. (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For nonpedunculated (sessile) PG, we suggest surgical excision of a narrow, deep, ellipse of skin beneath the lesion followed by wound closure with sutures to minimize the risk of recurrence. It is easier to control bleeding with full-thickness surgical excision than with shave excision or curettage. Punch excision may be used for small PGs. (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For small PG located in cosmetically sensitive areas in children, we suggest electrocautery, pulsed dye laser (PDL) treatment, or CO<sub>2</sub> laser ablation if laser therapies are available [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/4,58\" class=\"abstract_t\">4,58</a>]. Scarring is less conspicuous with laser therapy than with surgical therapies. In children it is less important to have histologic confirmation because the risk of malignant mimics of PG is lower than in adults. However, the need for sedation or general anesthesia in young children is a concern, especially if multiple treatment sessions are necessary. For adults with PG in cosmetically sensitive areas, the benefits of decreased scarring with laser therapy must be weighed against the lack of histopathologic confirmation. (See <a href=\"#H851407\" class=\"local\">'Laser therapy'</a> below.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with disseminated PG, we suggest surgical excision of a few lesions for histopathologic confirmation, followed by observation for spontaneous regression of the remaining lesions to avoid unnecessary scar formation [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For PGs that recur after treatment with shaving or nonsurgical modalities, we suggest surgical excision. (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We do not generally suggest cryotherapy or topical or intralesional therapies for PG. However, topical phenol may be an option for patients who refuse surgery or for small periungual PG. (See <a href=\"#H851423\" class=\"local\">'Topical and intralesional therapies'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H851362\"><span class=\"h2\">Treatment modalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatments for PG have not been adequately evaluated in randomized trials. Many treatment modalities have been described in retrospective series and case reports. In a review of 1162 PGs treated with 19 different modalities, surgical treatments, including full-thickness excision, shave excision, or curettage, were used in 65 percent of cases [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59\" class=\"abstract_t\">59</a>]. Nonsurgical treatments included cryotherapy, laser therapy, and intralesional or topical agents. The recurrence rates for different treatment modalities for PG are summarized in the table (<a href=\"image.htm?imageKey=DERM%2F82241\" class=\"graphic graphic_table graphicRef82241 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H851391\"><span class=\"h3\">Surgical treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical treatments for PG include full-thickness excision, shave excision, and curettage with or without electrocautery or laser photocoagulation of the base. Surgical treatment is the modality most frequently used to treat PG (<a href=\"image.htm?imageKey=DERM%2F82241\" class=\"graphic graphic_table graphicRef82241 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/1,5,59\" class=\"abstract_t\">1,5,59</a>]. </p><p>We suggest surgical rather than nonsurgical treatment for most PG. Surgical treatment permits histologic confirmation of the diagnosis and has acceptably low rates of recurrence. Surgical treatment may be combined with other interventions in the treatment of periungual or subungual PG. Scarring is the main drawback of surgical treatment. </p><p>Tissue that is obtained through excision, shaving, or curettage should be placed in formalin and sent for pathologic examination. For diagnostic purposes, excision or shave provide the optimal specimen for histologic examination. </p><p>The benefits of surgical therapy for PG have been described in small or retrospective studies: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a review of 753 PGs treated surgically, the recurrence rate for full-thickness excision and primary closure was 2.9 percent, whereas other surgical modalities, such as curettage and electrocautery or electrocautery alone, were associated with recurrence rates of 7 to 15 percent (<a href=\"image.htm?imageKey=DERM%2F82241\" class=\"graphic graphic_table graphicRef82241 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59\" class=\"abstract_t\">59</a>]. A recurrence rate of 13 percent has been reported for intraoral PG treated by shave excision [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a small randomized trial of clinically diagnosed PG, curettage and electrodessication of the base was superior to one cryotherapy treatment with respect to resolution of PG (97 versus 63 percent) and development of scar <span class=\"nowrap\">and/or</span> hypo- or hyperpigmentation (31 versus 43 percent) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/60\" class=\"abstract_t\">60</a>]. These results should be interpreted with caution, however, because typical cryotherapy regimens usually involve more than one treatment [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59,61\" class=\"abstract_t\">59,61</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 58 patients with periungual or subungual PG, successful treatment included removal of the causative agent if known (eg, foreign bodies or medications) and a two to three week course of high potency topical corticosteroids followed by curettage or nail avulsion and curettage for lesions of the nail bed [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/14\" class=\"abstract_t\">14</a>]. </p><p/><p class=\"headingAnchor\" id=\"H7075852\"><span class=\"h3\">Nonsurgical treatment</span></p><p class=\"headingAnchor\" id=\"H851407\"><span class=\"h4\">Laser therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laser therapy with pulsed dye laser (PDL) or CO<sub>2</sub> laser has been used for treatment of PG in children and adults [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/4,58,62,63\" class=\"abstract_t\">4,58,62,63</a>]. Laser therapy has also been used for photocoagulation of the base of the PG following surgical excision. The risk of scarring is lower with laser therapy than with surgical treatment. However, most forms of laser therapy do not provide specimens for histologic confirmation. Although the CO<sub>2</sub> laser has a cutting mode that may provide a tissue sample for pathology, the benefit of reduced scar is lost. </p><p>We suggest laser therapy with PDL or CO<sub>2</sub> laser treatment rather than surgical therapy for children with small PG in cosmetically sensitive areas; electrocautery is an option if laser therapy is not available (see <a href=\"#H502871753\" class=\"local\">'Electrocautery'</a> below). The CO<sub>2</sub> laser may be used as an alternative to surgical excision for removing PG of the oral cavity [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/64\" class=\"abstract_t\">64</a>]. </p><p>Multiple PDL treatment sessions are usually required because of the limited penetration of PDL in the dermis. (See <a href=\"topic.htm?path=laser-and-light-therapy-for-cutaneous-vascular-lesions\" class=\"medical medical_review\">&quot;Laser and light therapy for cutaneous vascular lesions&quot;</a>.) </p><p>In a review of 69 PGs treated with PDL, a recurrence occurred in three cases (<a href=\"image.htm?imageKey=DERM%2F82241\" class=\"graphic graphic_table graphicRef82241 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59\" class=\"abstract_t\">59</a>]. In a series of 22 children with small PG (average size 4 mm) treated with PDL, 15 required two to six laser treatments [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/58\" class=\"abstract_t\">58</a>]. Twenty patients responded to treatment and healed without scarring and two patients underwent subsequent shave excision and electrocautery. PDL and other vascular lasers do not allow histologic examination and may leave hypo- or hyperpigmentation.</p><p>The CO<sub>2</sub> laser generally removes PG lesions in one session [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/60\" class=\"abstract_t\">60</a>]. It may be used for destroying or cutting the lesion while coagulating the base [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/64\" class=\"abstract_t\">64</a>]. CO<sub>2</sub> laser used in cutting mode may provide a specimen suitable for histologic examination; however, this mode provides no advantage with respect to scarring. In a review of 102 PGs treated with CO<sub>2</sub> laser, five recurred [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59\" class=\"abstract_t\">59</a>]. In a prospective study, CO<sub>2</sub> laser was used with both continuous wave and pulsed modes, to treat 100 patients with PG [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/62\" class=\"abstract_t\">62</a>]. The lesion resolved after a single treatment in 98 patients. No scarring was reported in 88 patients. </p><p>The long-pulsed 1,064-nm Nd:YAG laser can be used following biopsy excision of PG and is suggested as a modality for difficult to treat locations such as the extremities or nail matrix, or for larger sessile PG [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/65,66\" class=\"abstract_t\">65,66</a>]. In a review of 20 patients with PG treated with excisional biopsy followed by Nd:YAG, clearance was obtained in 19 of the patients after one to four treatment sessions. One patient did not respond and was ultimately treated with CO<sub>2</sub> laser. Slight residual textural changes but no visible scars were noted in 53 percent of the treated patients [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/65\" class=\"abstract_t\">65</a>].</p><p class=\"headingAnchor\" id=\"H502871753\"><span class=\"h4\">Electrocautery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest electrocautery rather than full thickness surgical excision as an option for treatment of small PG located in cosmetically sensitive areas in children. Electrocautery is usually used in combination with curettage for the treatment of PG. Electrocautery alone may be used to destroy extremely small lesions.</p><p class=\"headingAnchor\" id=\"H851415\"><span class=\"h4\">Cryotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cryotherapy with liquid nitrogen has been described as a treatment for small PGs with a low risk of recurrence, scar formation, and hypo- or hyperpigmentation. However, we generally do not suggest cryotherapy because multiple treatments may be necessary and cryotherapy does not permit histologic confirmation.</p><p>In a review of 185 PGs, the recurrence rate for lesions treated with one or multiple liquid nitrogen applications was 1.6 percent (<a href=\"image.htm?imageKey=DERM%2F82241\" class=\"graphic graphic_table graphicRef82241 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59\" class=\"abstract_t\">59</a>]. In a prospective study, 135 children and adults with a clinical diagnosis of PG were treated with liquid nitrogen. Resolution of the lesion was obtained all patients after one to four treatment sessions, with minimal scar or hyperpigmentation [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/61\" class=\"abstract_t\">61</a>].</p><p>One small randomized trial compared cryotherapy (47 patients) with curettage and electrodessication of the base (42 patients) for PG [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/60\" class=\"abstract_t\">60</a>]. After one treatment, resolution was reported in 63 percent of patients in the cryotherapy group versus 97 percent of those in the curettage group. Scar <span class=\"nowrap\">and/or</span> hypo- or hyperpigmentation were reported in 43 percent of patients in the cryotherapy group and 31 percent in the curettage group. These results should be interpreted with caution, however, because typical cryotherapy regimens usually involve more than one treatment</p><p class=\"headingAnchor\" id=\"H851423\"><span class=\"h4\">Topical and intralesional therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of topical or intralesional treatments have been used to treat PG. These include sclerotherapy, intralesional corticosteroids, intralesional <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, and suture ligation. We generally do not suggest topical or intralesional therapies. Drawbacks of these modalities are the inability to perform histologic examination and, for some, a high recurrence rate.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sclerotherapy</strong> &ndash; Sclerotherapy with injection of <a href=\"topic.htm?path=ethanolamine-oleate-drug-information\" class=\"drug drug_general\">ethanolamine oleate</a>, <a href=\"topic.htm?path=sodium-tetradecyl-sulfate-drug-information\" class=\"drug drug_general\">sodium tetradecyl sulfate</a>, or <a href=\"topic.htm?path=polidocanol-drug-information\" class=\"drug drug_general\">polidocanol</a> has been described in a small series of patients, with complete resolution and inconspicuous scarring [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/67-70\" class=\"abstract_t\">67-70</a>]. A rare but potentially serious side effect of sclerotherapy is cutaneous necrosis, resulting from sclerosant extravasation or direct injection in a cutaneous arteriole.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Chemical cauterization</strong> &ndash; <a href=\"topic.htm?path=silver-nitrate-drug-information\" class=\"drug drug_general\">Silver nitrate</a> has been used in a small series of patients with PG on the hand [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/71\" class=\"abstract_t\">71</a>]. The mass was removed bluntly and the base of the lesion cauterized with silver nitrate. Complete resolution was reported in 11 patients after one to three treatments. Burning of the normal skin is a potential adverse effect of cauterization with silver nitrate. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical phenol </strong>&ndash;<strong> </strong>Topical phenol has been used for treatment of periungual PG [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/72\" class=\"abstract_t\">72</a>]. A piece of cotton dipped in phenol 98% solution is placed over the PG for three one-minute applications, repeated weekly until resolution. In a case series of 18 patients, 1 to 13 sessions were needed for clearance [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/72\" class=\"abstract_t\">72</a>]. Recurrence is more common with topical phenol than with surgical procedures. However, phenol application may be a treatment option for patients who refuse surgery or for smaller periungual PG. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical </strong><a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a> &ndash; Topical imiquimod has been used to treat PG in children and adults [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/73-77\" class=\"abstract_t\">73-77</a>]. Treatment regimens are variable, ranging from 6 days to 17 weeks (average 40 days), with frequency of application from 3 times per week up to 2 times per day, as tolerated. In a series of 10 children treated with topical imiquimod, one treatment failure was reported; no recurrence occurred in children responding to treatment during a follow-up of about 10 months [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/74\" class=\"abstract_t\">74</a>]. Side effects of imiquimod include irritation, erythema, skin necrosis, and secondary infection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical beta blockers</strong> &ndash; Topical <a href=\"topic.htm?path=timolol-drug-information\" class=\"drug drug_general\">timolol</a>, a nonselective beta-adrenergic antagonist, has been used to treat PG in a small number of children and adults with varying results [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/78-80\" class=\"abstract_t\">78-80</a>]. In a series of six children with recurrent or primary diagnosis of PG, timolol applied two to three times a day induced at least a partial response by two months [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/78\" class=\"abstract_t\">78</a>]. In another small study of 10 adult patients with periungual PG, <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a> 1% cream applied overnight under occlusion for 30 to 45 days induced complete resolution of all lesions located on the fingernails, including those secondary to targeted chemotherapy for cancer [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/79\" class=\"abstract_t\">79</a>]. However, topical propranolol was not effective for PGs located on the toenails.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Suture ligation </strong>&ndash; Ligation of the lesion base using soft (absorbable) suture material has been used in children with facial PG [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/81-83\" class=\"abstract_t\">81-83</a>]. Following ligation, the tumor becomes necrotic and falls off in days to weeks. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intralesional injection</strong> &ndash; Intralesional injection of <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, corticosteroids, or absolute ethanol is described in a small number of case reports [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/84-87\" class=\"abstract_t\">84-87</a>].</p><p/><p class=\"headingAnchor\" id=\"H2043216\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrence rates following treatment range from 0 to 15 percent depending upon the modality of therapy and location of the PG (<a href=\"image.htm?imageKey=DERM%2F82241\" class=\"graphic graphic_table graphicRef82241 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/3,4\" class=\"abstract_t\">3,4</a>]. (See <a href=\"#H3446840\" class=\"local\">'Management'</a> above.)</p><p class=\"headingAnchor\" id=\"H3446847\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the etiology of PG is not well understood, there are no measures to prevent the de novo development of a lesion. The selection of a treatment modality with high clearance rate may prevent recurrence.</p><p class=\"headingAnchor\" id=\"H32143786\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pyogenic granuloma (PG) or lobular capillary hemangioma is a benign vascular tumor of the skin (<a href=\"image.htm?imageKey=DERM%2F60189\" class=\"graphic graphic_picture graphicRef60189 \">picture 2A</a>) or mucous membranes (<a href=\"image.htm?imageKey=PC%2F66965%7EDERM%2F67395%7EDERM%2F52429\" class=\"graphic graphic_picture graphicRef66965 graphicRef67395 graphicRef52429 \">picture 2B, 3B-C</a>) characterized by rapid growth and friable surface. Pyogenic granuloma occurs in patients of all ages, with a peak incidence in the second and third decades of life. (See <a href=\"#H3446791\" class=\"local\">'Introduction'</a> above and <a href=\"#H1291997\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The cause of PG is unknown. Reported trigger factors include trauma and medications. (See <a href=\"#H3446805\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PG grows rapidly over weeks to months. The lesions may be pedunculated or sessile, with a characteristic epithelial collarette at the base (<a href=\"image.htm?imageKey=DERM%2F60189\" class=\"graphic graphic_picture graphicRef60189 \">picture 2A</a>). The surface is friable, bleeds profusely after minor trauma, and may become ulcerated. Pyogenic granulomas are usually solitary, but multiple satellite lesions and disseminated forms also occur. (See <a href=\"#H3446812\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histologically, pyogenic granuloma consists of a proliferation of capillary vessels with stromal edema and a mixed inflammatory infiltrate (<a href=\"image.htm?imageKey=DERM%2F71936%7EDERM%2F50978\" class=\"graphic graphic_picture graphicRef71936 graphicRef50978 \">picture 5A-B</a>). (See <a href=\"#H3446819\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of PG is usually straightforward, based upon the clinical history of an erythematous, dome-shaped papule that bleeds easily and has developed over a few days to weeks (<a href=\"image.htm?imageKey=DERM%2F52128%7EDERM%2F52429\" class=\"graphic graphic_picture graphicRef52128 graphicRef52429 \">picture 3A, 3C</a>). However, histologic confirmation is desirable because several benign and malignant lesions can mimic pyogenic granuloma. (See <a href=\"#H3446826\" class=\"local\">'Diagnosis and differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment is usually required for pyogenic granuloma because of frequent ulceration and bleeding. There are few randomized trials comparing treatments for PG and no consensus regarding the optimal approach. (See <a href=\"#H851348\" class=\"local\">'Therapeutic approach'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For pedunculated PG, we suggest shave excision or curettage followed by cautery of the base rather than full thickness excision (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For nonpedunculated PG, we suggest surgical excision followed by wound closure with sutures rather than shave excision or nonsurgical modalities (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For small PG located in cosmetically sensitive areas in children, we suggest electrocautery, pulsed dye laser treatment, or CO<sub>2</sub> laser ablation if laser therapies are available (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H502871753\" class=\"local\">'Electrocautery'</a> above and <a href=\"#H851407\" class=\"local\">'Laser therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For PGs that recur after treatment with shaving or nonsurgical modalities, we suggest surgical excision (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H851391\" class=\"local\">'Surgical treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/1\" class=\"nounderline abstract_t\">Mills SE, Cooper PH, Fechner RE. Lobular capillary hemangioma: the underlying lesion of pyogenic granuloma. A study of 73 cases from the oral and nasal mucous membranes. Am J Surg Pathol 1980; 4:470.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/2\" class=\"nounderline abstract_t\">Harris MN, Desai R, Chuang TY, et al. Lobular capillary hemangiomas: An epidemiologic report, with emphasis on cutaneous lesions. J Am Acad Dermatol 2000; 42:1012.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/3\" class=\"nounderline abstract_t\">Giblin AV, Clover AJ, Athanassopoulos A, Budny PG. Pyogenic granuloma - the quest for optimum treatment: audit of treatment of 408 cases. J Plast Reconstr Aesthet Surg 2007; 60:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/4\" class=\"nounderline abstract_t\">Pagliai KA, Cohen BA. Pyogenic granuloma in children. Pediatr Dermatol 2004; 21:10.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/5\" class=\"nounderline abstract_t\">Patrice SJ, Wiss K, Mulliken JB. Pyogenic granuloma (lobular capillary hemangioma): a clinicopathologic study of 178 cases. Pediatr Dermatol 1991; 8:267.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/6\" class=\"nounderline abstract_t\">Saravana GH. Oral pyogenic granuloma: a review of 137 cases. Br J Oral Maxillofac Surg 2009; 47:318.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/7\" class=\"nounderline abstract_t\">Gord&oacute;n-N&uacute;&ntilde;ez MA, de Vasconcelos Carvalho M, Benevenuto TG, et al. Oral pyogenic granuloma: a retrospective analysis of 293 cases in a Brazilian population. J Oral Maxillofac Surg 2010; 68:2185.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/8\" class=\"nounderline abstract_t\">Kroumpouzos G, Cohen LM. Dermatoses of pregnancy. J Am Acad Dermatol 2001; 45:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/9\" class=\"nounderline abstract_t\">Piguet V, Borradori L. Pyogenic granuloma-like lesions during capecitabine therapy. Br J Dermatol 2002; 147:1270.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/10\" class=\"nounderline abstract_t\">Chen SY, Takeuchi S, Urabe K, et al. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma. J Cutan Pathol 2008; 35:722.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/11\" class=\"nounderline abstract_t\">Arbiser JL, Weiss SW, Arbiser ZK, et al. Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol 2001; 44:193.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/12\" class=\"nounderline abstract_t\">Lim YH, Douglas SR, Ko CJ, et al. Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic Granuloma. J Invest Dermatol 2015; 135:1698.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/13\" class=\"nounderline abstract_t\">Blackwell MG, Itinteang T, Chibnall AM, et al. Expression of embryonic stem cell markers in pyogenic granuloma. J Cutan Pathol 2016; 43:1096.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/14\" class=\"nounderline abstract_t\">Piraccini BM, Bellavista S, Misciali C, et al. Periungual and subungual pyogenic granuloma. Br J Dermatol 2010; 163:941.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/15\" class=\"nounderline abstract_t\">Cheney-Peters D, Lund TC. Oral Pyogenic Granuloma After Bone Marrow Transplant in the Pediatric/Adolescent Population: Report of 5 Cases. J Pediatr Hematol Oncol 2016; 38:570.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/16\" class=\"nounderline abstract_t\">Amin A, Shwayder T. Acitretin + EHK = PG: Toe web pyogenic granuloma in a man with total body epidermolytic hyperkeratosis on acitretin--report of a unique occurrence. Dermatol Nurs 2009; 21:345.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/17\" class=\"nounderline abstract_t\">Exner JH, Dahod S, Pochi PE. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol 1983; 119:808.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/18\" class=\"nounderline abstract_t\">Dawkins MA, Clark AR, Feldman SR. Pyogenic granuloma-like lesion associated with topical tazarotene therapy. J Am Acad Dermatol 2000; 43:154.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/19\" class=\"nounderline abstract_t\">Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/20\" class=\"nounderline abstract_t\">High WA. Gefitinib: a cause of pyogenic granulomalike lesions of the nail. Arch Dermatol 2006; 142:939.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/21\" class=\"nounderline abstract_t\">Curr N, Saunders H, Murugasu A, et al. Multiple periungual pyogenic granulomas following systemic 5-fluorouracil. Australas J Dermatol 2006; 47:130.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/22\" class=\"nounderline abstract_t\">Lee L, Miller PA, Maxymiw WG, et al. Intraoral pyogenic granuloma after allogeneic bone marrow transplant. Report of three cases. Oral Surg Oral Med Oral Pathol 1994; 78:607.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/23\" class=\"nounderline abstract_t\">Devillers C, Vanhooteghem O, Henrijean A, et al. Subungueal pyogenic granuloma secondary to docetaxel therapy. Clin Exp Dermatol 2009; 34:251.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/24\" class=\"nounderline abstract_t\">Lenczowski JM, Cassarino DS, Jain A, Turner ML. Disseminated vascular papules in an immunodeficient patient being treated with granulocyte colony-stimulating factor. J Am Acad Dermatol 2003; 49:105.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/25\" class=\"nounderline abstract_t\">Bouscarat F, Bouchard C, Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 1998; 338:1776.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/26\" class=\"nounderline abstract_t\">Dika E, Barisani A, Vaccari S, et al. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia. J Drugs Dermatol 2013; 12:512.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/27\" class=\"nounderline abstract_t\">Henning B, Stieger P, Kamarachev J, et al. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Res 2016; 26:304.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/28\" class=\"nounderline abstract_t\">Swerlick RA, Cooper PH. Pyogenic granuloma (lobular capillary hemangioma) within port-wine stains. J Am Acad Dermatol 1983; 8:627.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/29\" class=\"nounderline abstract_t\">Beers BB, Rustad OJ, Vance JC. Pyogenic granuloma following laser treatment of a port-wine stain. Cutis 1988; 41:266.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/30\" class=\"nounderline abstract_t\">Cheah S, DeKoven J. Pyogenic granuloma complicating pulsed-dye laser therapy for cherry angioma. Australas J Dermatol 2009; 50:141.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/31\" class=\"nounderline abstract_t\">Olbricht SM, Stern RS, Tang SV, et al. Complications of cutaneous laser surgery. A survey. Arch Dermatol 1987; 123:345.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/32\" class=\"nounderline abstract_t\">Groesser L, Peterhof E, Evert M, et al. BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma. J Invest Dermatol 2016; 136:481.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/33\" class=\"nounderline abstract_t\">Moffatt DC, Warwryko P, Singh H. Pyogenic granuloma: an unusual cause of massive gastrointestinal bleeding from the small bowel. Can J Gastroenterol 2009; 23:261.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/34\" class=\"nounderline abstract_t\">Garzon MC, Enjolras O, Frieden IJ. Vascular tumors and vascular malformations: evidence for an association. J Am Acad Dermatol 2000; 42:275.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/35\" class=\"nounderline abstract_t\">Ozdemir M, Engin B. Pyogenic granuloma following treatment of a port-wine stain with intense pulsed ligt. J Cosmet Dermatol 2007; 6:270.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/36\" class=\"nounderline abstract_t\">Aghaei S. Pyogenic granuloma arising in port-wine stain after cryotherapy. Dermatol Online J 2003; 9:16.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/37\" class=\"nounderline abstract_t\">Wlotzke U, Hohenleutner U, Abd-El-Raheem TA, et al. Side-effects and complications of flashlamp-pumped pulsed dye laser therapy of port-wine stains. A prospective study. Br J Dermatol 1996; 134:475.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/38\" class=\"nounderline abstract_t\">Wilson BB, Greer KE, Cooper PH. Eruptive disseminated lobular capillary hemangioma (pyogenic granuloma). J Am Acad Dermatol 1989; 21:391.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/39\" class=\"nounderline abstract_t\">Palmero ML, Pope E. Eruptive pyogenic granulomas developing after drug hypersensitivity reaction. J Am Acad Dermatol 2009; 60:855.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/40\" class=\"nounderline abstract_t\">Shah M, Kingston TP, Cotterill JA. Eruptive pyogenic granulomas: a successfully treated patient and review of the literature. Br J Dermatol 1995; 133:795.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/41\" class=\"nounderline abstract_t\">Ceyhan AM, Basak PY, Akkaya VB, et al. A case of multiple, eruptive pyogenic granuloma developed on a region of the burned skin: can erythromycin be a treatment option? J Burn Care Res 2007; 28:754.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/42\" class=\"nounderline abstract_t\">Baselga E, Wassef M, Lopez S, et al. Agminated, eruptive pyogenic granuloma-like lesions developing over congenital vascular stains. Pediatr Dermatol 2012; 29:186.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/43\" class=\"nounderline abstract_t\">Blickenstaff RD, Roenigk RK, Peters MS, Goellner JR. Recurrent pyogenic granuloma with satellitosis. J Am Acad Dermatol 1989; 21:1241.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/44\" class=\"nounderline abstract_t\">Dillman AM, Miller RC, Hansen RC. Multiple pyogenic granulomata in childhood. Pediatr Dermatol 1991; 8:28.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/45\" class=\"nounderline abstract_t\">Benmously-Mlika R, Hammami H, Mokhtar I. Violaceous papules of the back: a quiz. Diagnosis: recurrent pyogenic granuloma or Warner and Wilson-Jones syndrome (1, 2). Acta Derm Venereol 2011; 91:491.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/46\" class=\"nounderline abstract_t\">Frieden IJ, Esterly NB. Pyogenic granulomas of infancy masquerading as strawberry hemangiomas. Pediatrics 1992; 90:989.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/47\" class=\"nounderline abstract_t\">Browning JC, Eldin KW, Kozakewich HP, et al. Congenital disseminated pyogenic granuloma. Pediatr Dermatol 2009; 26:323.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/48\" class=\"nounderline abstract_t\">Nappi O, Wick MR. Disseminated lobular capillary hemangioma (pyogenic granuloma). A clinicopathologic study of two cases. Am J Dermatopathol 1986; 8:379.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/49\" class=\"nounderline abstract_t\">Al Dhaybi R, Powell J, McCuaig C, Kokta V. Differentiation of vascular tumors from vascular malformations by expression of Wilms tumor 1 gene: evaluation of 126 cases. J Am Acad Dermatol 2010; 63:1052.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/50\" class=\"nounderline abstract_t\">Lawley LP, Cerimele F, Weiss SW, et al. Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch Dermatol 2005; 141:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/51\" class=\"nounderline abstract_t\">Kuzu I, Bicknell R, Harris AL, et al. Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol 1992; 45:143.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/52\" class=\"nounderline abstract_t\">Zaballos P, Llambrich A, Cu&eacute;llar F, et al. Dermoscopic findings in pyogenic granuloma. Br J Dermatol 2006; 154:1108.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/53\" class=\"nounderline abstract_t\">Hoffman DM, Shwayder T. A crusted, friable papule on the scalp of a 17-month-old boy. Pediatr Dermatol 2009; 26:615.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/54\" class=\"nounderline abstract_t\">Gombos Z, Zhang PJ. Glomus tumor. Arch Pathol Lab Med 2008; 132:1448.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/55\" class=\"nounderline abstract_t\">Megaly M, Boshra N. Pyogenic granuloma-like Kaposi's sarcoma. Lancet 2015.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/56\" class=\"nounderline abstract_t\">L&oslash;es S, Tornes K. Misinterpretation of histopathological results as an important risk factor for unneeded surgery - case report of a &quot;near miss&quot; event in a pregnant woman. Patient Saf Surg 2008; 2:14.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/57\" class=\"nounderline abstract_t\">Bozkurt M, K&uuml;lah&ccedil;i Y, Zor F, A&#351;kar I. Multiple giant disseminated pyogenic granuloma in a burn lesion. J Burn Care Res 2006; 27:247.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/58\" class=\"nounderline abstract_t\">Tay YK, Weston WL, Morelli JG. Treatment of pyogenic granuloma in children with the flashlamp-pumped pulsed dye laser. Pediatrics 1997; 99:368.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/59\" class=\"nounderline abstract_t\">Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: a review. J Plast Reconstr Aesthet Surg 2011; 64:1216.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/60\" class=\"nounderline abstract_t\">Ghodsi SZ, Raziei M, Taheri A, et al. Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial. Br J Dermatol 2006; 154:671.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/61\" class=\"nounderline abstract_t\">Mirshams M, Daneshpazhooh M, Mirshekari A, et al. Cryotherapy in the treatment of pyogenic granuloma. J Eur Acad Dermatol Venereol 2006; 20:788.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/62\" class=\"nounderline abstract_t\">Raulin C, Greve B, Hammes S. The combined continuous-wave/pulsed carbon dioxide laser for treatment of pyogenic granuloma. Arch Dermatol 2002; 138:33.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/63\" class=\"nounderline abstract_t\">Sud AR, Tan ST. Pyogenic granuloma-treatment by shave-excision and/or pulsed-dye laser. J Plast Reconstr Aesthet Surg 2010; 63:1364.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/64\" class=\"nounderline abstract_t\">Jafarzadeh H, Sanatkhani M, Mohtasham N. Oral pyogenic granuloma: a review. J Oral Sci 2006; 48:167.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/65\" class=\"nounderline abstract_t\">Hammes S, Kaiser K, Pohl L, et al. Pyogenic granuloma: treatment with the 1,064-nm long-pulsed neodymium-doped yttrium aluminum garnet laser in 20 patients. Dermatol Surg 2012; 38:918.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/66\" class=\"nounderline abstract_t\">Bourguignon R, Paquet P, Pi&eacute;rard-Franchimont C, Pi&eacute;rard GE. Treatment of pyogenic granulomas with the Nd-YAG laser. J Dermatolog Treat 2006; 17:247.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/67\" class=\"nounderline abstract_t\">Matsumoto K, Nakanishi H, Seike T, et al. Treatment of pyogenic granuloma with a sclerosing agent. Dermatol Surg 2001; 27:521.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/68\" class=\"nounderline abstract_t\">Hong SK, Lee HJ, Seo JK, et al. Reactive vascular lesions treated using ethanolamine oleate sclerotherapy. Dermatol Surg 2010; 36:1148.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/69\" class=\"nounderline abstract_t\">Moon SE, Hwang EJ, Cho KH. Treatment of pyogenic granuloma by sodium tetradecyl sulfate sclerotherapy. Arch Dermatol 2005; 141:644.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/70\" class=\"nounderline abstract_t\">Carvalho RA, Neto V. Letter: Polidocanol sclerotherapy for the treatment of pyogenic granuloma. Dermatol Surg 2010; 36 Suppl 2:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/71\" class=\"nounderline abstract_t\">Quitkin HM, Rosenwasser MP, Strauch RJ. The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg Am 2003; 28:435.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/72\" class=\"nounderline abstract_t\">Losa Iglesias ME, Becerro de Bengoa Vallejo R. Topical phenol as a conservative treatment for periungual pyogenic granuloma. Dermatol Surg 2010; 36:675.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/73\" class=\"nounderline abstract_t\">Ezzell TI, Fromowitz JS, Ramos-Caro FA. Recurrent pyogenic granuloma treated with topical imiquimod. J Am Acad Dermatol 2006; 54:S244.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/74\" class=\"nounderline abstract_t\">Tritton SM, Smith S, Wong LC, et al. Pyogenic granuloma in ten children treated with topical imiquimod. Pediatr Dermatol 2009; 26:269.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/75\" class=\"nounderline abstract_t\">Gencoglan G, Inanir I, G&uuml;nd&uuml;z K. Pyogenic granuloma in two children successfully treated with imiquimod 5% cream. Pediatr Dermatol 2009; 26:366.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/76\" class=\"nounderline abstract_t\">Goldenberg G, Krowchuk DP, Jorizzo JL. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 2006; 17:121.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/77\" class=\"nounderline abstract_t\">Georgiou S, Monastirli A, Pasmatzi E, Tsambaos D. Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. Clin Exp Dermatol 2008; 33:454.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/78\" class=\"nounderline abstract_t\">Wine Lee L, Goff KL, Lam JM, et al. Treatment of pediatric pyogenic granulomas using &beta;-adrenergic receptor antagonists. Pediatr Dermatol 2014; 31:203.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/79\" class=\"nounderline abstract_t\">Piraccini BM, Alessandrini A, Dika E, et al. Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients. J Eur Acad Dermatol Venereol 2016; 30:901.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/80\" class=\"nounderline abstract_t\">Gupta D, Singh N, Thappa DM. Is timolol an effective treatment for pyogenic granuloma? Int J Dermatol 2016; 55:592.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/81\" class=\"nounderline abstract_t\">Masu T, Okuyama R, Aiba S, Tsunoda T. Ligation of pyogenic granuloma on a face. Int J Dermatol 2010; 49:1075.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/82\" class=\"nounderline abstract_t\">H&ouml;lbe HC, Frosch PJ, Herbst RA. Surgical pearl: ligation of the base of pyogenic granuloma--an atraumatic, simple, and cost-effective procedure. J Am Acad Dermatol 2003; 49:509.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/83\" class=\"nounderline abstract_t\">Scalvenzi M, Balato A, Francia MG, Lembo S. Pyogenic granuloma to rope! J Eur Acad Dermatol Venereol 2008; 22:499.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/84\" class=\"nounderline abstract_t\">Parisi E, Glick PH, Glick M. Recurrent intraoral pyogenic granuloma with satellitosis treated with corticosteroids. Oral Dis 2006; 12:70.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/85\" class=\"nounderline abstract_t\">Daya M. Complete resolution of a recurrent giant pyogenic granuloma on the palm of the hand following single dose of intralesional bleomycin injection. J Plast Reconstr Aesthet Surg 2010; 63:e331.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/86\" class=\"nounderline abstract_t\">Niiyama S, Amoh Y, Katsuoka K. Pyogenic granuloma that responded to local injection of steroid. J Plast Reconstr Aesthet Surg 2009; 62:e153.</a></li><li><a href=\"https://www.uptodate.com/contents/pyogenic-granuloma-lobular-capillary-hemangioma/abstract/87\" class=\"nounderline abstract_t\">Ichimiya M, Yoshikawa Y, Hamamoto Y, Muto M. Successful treatment of pyogenic granuloma with injection of absolute ethanol. J Dermatol 2004; 31:342.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13736 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H32143786\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H3446791\" id=\"outline-link-H3446791\">INTRODUCTION</a></li><li><a href=\"#H1291997\" id=\"outline-link-H1291997\">EPIDEMIOLOGY</a></li><li><a href=\"#H3446805\" id=\"outline-link-H3446805\">PATHOGENESIS</a></li><li><a href=\"#H3446812\" id=\"outline-link-H3446812\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H3446819\" id=\"outline-link-H3446819\">PATHOLOGY</a></li><li><a href=\"#H3446826\" id=\"outline-link-H3446826\">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H851335\" id=\"outline-link-H851335\">NATURAL HISTORY</a></li><li><a href=\"#H3446840\" id=\"outline-link-H3446840\">MANAGEMENT</a><ul><li><a href=\"#H851348\" id=\"outline-link-H851348\">Therapeutic approach</a></li><li><a href=\"#H851362\" id=\"outline-link-H851362\">Treatment modalities</a><ul><li><a href=\"#H851391\" id=\"outline-link-H851391\">- Surgical treatment</a></li><li><a href=\"#H7075852\" id=\"outline-link-H7075852\">- Nonsurgical treatment</a><ul><li><a href=\"#H851407\" id=\"outline-link-H851407\">Laser therapy</a></li><li><a href=\"#H502871753\" id=\"outline-link-H502871753\">Electrocautery</a></li><li><a href=\"#H851415\" id=\"outline-link-H851415\">Cryotherapy</a></li><li><a href=\"#H851423\" id=\"outline-link-H851423\">Topical and intralesional therapies</a></li></ul></li></ul></li></ul></li><li><a href=\"#H2043216\" id=\"outline-link-H2043216\">PROGNOSIS</a></li><li><a href=\"#H3446847\" id=\"outline-link-H3446847\">PREVENTION</a></li><li><a href=\"#H32143786\" id=\"outline-link-H32143786\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13736|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/59124\" class=\"graphic graphic_picture\">- Port wine stain - V2 infant</a></li><li><a href=\"image.htm?imageKey=PEDS/58831\" class=\"graphic graphic_picture\">- Adult with SWS and port wine stain</a></li><li><a href=\"image.htm?imageKey=DERM/60189\" class=\"graphic graphic_picture\">- Pyogenic granuloma lip</a></li><li><a href=\"image.htm?imageKey=DERM/52128\" class=\"graphic graphic_picture\">- Pyogenic granuloma 2</a></li><li><a href=\"image.htm?imageKey=DERM/67395\" class=\"graphic graphic_picture\">- Pyogenic granuloma - chest</a></li><li><a href=\"image.htm?imageKey=DERM/52429\" class=\"graphic graphic_picture\">- Pyogenic granuloma collarette</a></li><li><a href=\"image.htm?imageKey=PC/66965\" class=\"graphic graphic_picture\">- Pyogenic granuloma gingival mucosa</a></li><li><a href=\"image.htm?imageKey=DERM/62759\" class=\"graphic graphic_picture\">- Pyogenic granuloma multiple</a></li><li><a href=\"image.htm?imageKey=DERM/71936\" class=\"graphic graphic_picture\">- Pyogenic granuloma histology 1</a></li><li><a href=\"image.htm?imageKey=DERM/50978\" class=\"graphic graphic_picture\">- Pyogenic granuloma histology 2</a></li><li><a href=\"image.htm?imageKey=DERM/57957\" class=\"graphic graphic_picture\">- Pyogenic granuloma dermoscopy</a></li><li><a href=\"image.htm?imageKey=PEDS/60004\" class=\"graphic graphic_picture\">- Superficial hemangioma</a></li><li><a href=\"image.htm?imageKey=DERM/77094\" class=\"graphic graphic_picture\">- Glomus tumor</a></li><li><a href=\"image.htm?imageKey=DERM/70615\" class=\"graphic graphic_picture\">- Verruca vulgaris - hand</a></li><li><a href=\"image.htm?imageKey=DERM/56924\" class=\"graphic graphic_picture\">- Verruca vulgaris</a></li><li><a href=\"image.htm?imageKey=DERM/62791\" class=\"graphic graphic_picture\">- Amelanotic melanoma 2</a></li><li><a href=\"image.htm?imageKey=DERM/60026\" class=\"graphic graphic_picture\">- Cutaneous squamous cell carcinoma</a></li><li><a href=\"image.htm?imageKey=DERM/55042\" class=\"graphic graphic_picture\">- Keratoacanthoma - face</a></li><li><a href=\"image.htm?imageKey=ONC/61190\" class=\"graphic graphic_picture\">- Nodular basal cell carcinomas</a></li><li><a href=\"image.htm?imageKey=DERM/65704\" class=\"graphic graphic_picture\">- Nodular basal cell carcinoma</a></li><li><a href=\"image.htm?imageKey=DERM/61313\" class=\"graphic graphic_picture\">- Dermoscopy basal cell carcinoma</a></li><li><a href=\"image.htm?imageKey=PC/80323\" class=\"graphic graphic_picture\">- Kaposis sarcoma eyelid</a></li><li><a href=\"image.htm?imageKey=ID/78497\" class=\"graphic graphic_picture\">- Bacillary angiomatosis</a></li><li><a href=\"image.htm?imageKey=ID/76323\" class=\"graphic graphic_picture\">- Bacillary angiomatosis in HIV</a></li><li><a href=\"image.htm?imageKey=ID/54383\" class=\"graphic graphic_picture\">- Light microscopy of Bartonella </a></li><li><a href=\"image.htm?imageKey=ID/62100\" class=\"graphic graphic_picture\">- Warthin Starry staining</a></li></ul></li><li><div id=\"DERM/13736|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/82241\" class=\"graphic graphic_table\">- Pyogenic granuloma treatments and recurrence rates</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aids-related-kaposi-sarcoma-staging-and-treatment\" class=\"medical medical_review\">AIDS-related Kaposi sarcoma: Staging and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">Capillary malformations (port wine stains) and associated syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment\" class=\"medical medical_review\">Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-cutaneous-squamous-cell-carcinoma-scc\" class=\"medical medical_review\">Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">Cutaneous side effects of conventional chemotherapy agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-warts-common-plantar-and-flat-warts\" class=\"medical medical_review\">Cutaneous warts (common, plantar, and flat warts)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-features-of-basal-cell-carcinoma\" class=\"medical medical_review\">Epidemiology, pathogenesis, and clinical features of basal cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hemangiomas-epidemiology-pathogenesis-clinical-features-and-complications\" class=\"medical medical_review\">Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=laser-and-light-therapy-for-cutaneous-vascular-lesions\" class=\"medical medical_review\">Laser and light therapy for cutaneous vascular lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-skin-hair-nails-and-mucous-membranes\" class=\"medical medical_review\">Maternal adaptations to pregnancy: Skin, hair, nails, and mucous membranes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=melanoma-clinical-features-and-diagnosis\" class=\"medical medical_review\">Melanoma: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapidly-involuting-congenital-hemangioma-rich-and-noninvoluting-congenital-hemangioma-nich\" class=\"medical medical_review\">Rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spitzoid-melanocytic-neoplasms-spitz-nevus-and-atypical-spitz-tumors\" class=\"medical medical_review\">Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)</a></li></ul></div></div>","javascript":null}